Is Ocugen going out of business?

OCUGEN, INC. (OCGN) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

OCUGEN, INC. (OCGN) scores 14 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Stable

17-25 mo of estimated runway from 2026-06-30, based on $100M of cash and short-term investments against $57.1M of annual burn. Adjusted shares outstanding increased 14.1% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

-5.2% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• FCF margin: -1295.01%
• Interest coverage: -13.3x
• Revenue CAGR (3Y): -1.57%
• Return on Assets: -54.62%
• Debt Maturity Runway: 99% long-term (Long-term focused)
• Revenue growth YoY: 8.38% (YoY)
• Cash Runway (years): 1.75y
• Cash Burn Deceleration: -60.77% QoQ improvement (Worsening)
• Price / Sales: 81.8x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Shares dilution YoY: 14.08% (YoY)

Read from filings through 2026-08-06.

Price as of 2026-09-07.